查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1871026

按产品类型、技术、最终用户、应用、分销通路和材质分類的氧合器市场－2025年至2032年全球预测

Artificial Lung Market by Product Type, Technology, End User, Application, Distribution Channel, Material Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，人工肺市场规模将达到 152.4 亿美元，复合年增长率为 9.02%。

关键市场统计数据
基准年 2024 76.3亿美元
预计年份：2025年 83.3亿美元
预测年份 2032 152.4亿美元
复合年增长率 (%) 9.02%

全面介绍不断发展的人工肺领域，将设备工程的进步与不断变化的临床实践和应用需求联繫起来。

人工肺领域正迅速发展成熟，这得益于加护治疗创新和先进生物材料工程的融合。推动这项发展的主要因素是临床上对人工呼吸器替代方案的迫切需求，以及对改善严重呼吸衰竭患者预后的迫切愿望。新兴的设备架构旨在以更高的生物相容性和便携性来模拟肺部气体交换，同时治疗流程也在不断调整，以便更早将体外支持纳入治疗路径。随着人们的关注点从急性住院治疗转向门诊和居家支持，研发人员和医疗服务提供者必须在加护治疗级别的性能、以用户为中心的设计以及长期安全性之间取得平衡。

材料技术的创新、支撑系统的微型化以及医疗保健服务模式的改变，共同重新定义了人工肺的采用和整合轨迹。

随着临床团队寻求能够提供稳定气体交换并最大限度地减少血栓形成和发炎反应的设备，人工肺技术的研发和应用正经历着变革性的转变。膜材料的创新正以高性能陶瓷和工程化中空纤维取代传统聚合物，从而提升了耐用性和血液相容性。同时，驱动主机的小型化和血流动力学管理演算法的改进，使得更灵活的部署模式成为可能，包括便携式体外装置以及用于长期支援的植入装置。

评估 2025 年实施的进口关税提高对供应链韧性、筹资策略和产品开发时间表的结构性和营运性影响。

2025年实施的新关税制度和贸易措施为氧合器生产和分销的整个供应链带来了明显的摩擦。关键进口零件（例如精密泵浦、特种膜和生物相容性聚合物）的关税提高，增加了依赖跨境采购的组装的到岸成本。因此，采购团队和生产负责人正在重新评估供应商集中度、避险策略和合约条款，以维持利润率和供应的连续性。

将产品架构、膜技术、终端用户工作流程、应用场景、分销方式和材料选择与商业化策略联繫起来的实用细分洞察

要了解人工肺领域价值创造的组成，需要深入了解产品、技术、终端用户、应用、分销管道和材料类型的细分情况。产品差异化涵盖体外膜氧合（ECMO）系统和正在研发中的植入式氧合器，其中ECMO系统又可进一步细分为插管、主机、氧合器和泵，这些部件共同决定了手术的复杂性和面积。技术选择范围广泛，从陶瓷膜和平板膜到中空纤维膜，中空纤维膜中聚醚砜和聚丙烯的不同混合物决定了其在渗透性、耐久性和血液相容性方面的权衡。

区域策略挑战包括协调监管差异、临床基础设施和製造地，以加速人工肺技术在全球市场的普及。

区域趋势正对美洲、欧洲、中东和非洲以及亚太地区的监管预期、报销机制和生产物流产生深远影响。在美洲，临床研究网络和加护治疗基础设施为先进的体外疗法提供了支持，但市场准入和规模化发展需要应对不同的支付方体系和医院采购通讯协定。同时，欧洲、中东和非洲地区的法规环境十分复杂，各国在协调统一的同时，也存在着各自不同的评估标准和采购规范，这共同决定了实施时间表和临床证据要求。

实现永续差异化的主要企业模式和竞争要务：- 优先发展膜技术创新 - 更严格的生产流程 - 建立临床证据 - 整合销售管道

人工肺领域的竞争由成熟的医疗设备製造商、专业组件供应商以及将转化研究成果转化为商业原型产品的临床创新者共同推动。领先企业透过在膜科学、泵浦效率和整合感测器系统方面的投资，在性能、易用性和生命週期成本方面实现差异化竞争。设备原始设备製造商 (OEM) 与材料专家之间的策略联盟日益普遍，从而能够共同开发膜结构和血液相容性涂层，以减少血栓形成和发炎反应。

针对如何整合模组化设计、供应商多元化、临床证据项目和客製化商业模式以推动应用和增强韧性，提出具有重大影响力的领导建议

产业领导者应推行一项综合性议程，同时兼顾技术复杂性、供应链韧性和临床应用路径。优先采用模组化设备架构可以加快替代供应商的资格认证，并支援迭代式产品更新，而无需进行平台范围的重新设计。对膜和涂层技术的投资应与严格的血液相容性测试和人体工学设计相结合，以减少不利事件并简化临床医生的工作流程。在供应链方面，组件采购多元化并考虑区域性製造地可以缩短关键组件的前置作业时间，同时降低关税风险和物流中断的影响。

一种透明、以证据为导向的调查方法，整合了临床医生访谈、材料和设备分析、供应链图谱绘製以及情境测试，以支持策略决策。

我们的研究途径结合了多方面的证据基础、定性专家访谈和结构化分析，以全面了解氧合器的现状。主要研究内容包括与临床医生、生物医学工程师、监管顾问和采购专业人员的讨论，以了解临床工作流程、设备性能优先事项以及实际应用中的障碍。辅助研究涵盖同侪审查文献、监管指导文件、专利和製造商技术规范，以验证技术趋势和材料科学的进步。设备架构和供应链布局的比较分析有助于评估可製造性和物流风险。

这是一项综合性研究，它结合了突破性的材料科学、设备便携性、监管完整性和供应链韧性，为临床应用和商业化规划了一条切实可行的路径。

总之，膜材料的进步、设备的微型化以及系统整合度的提高，共同促成了氧合器技术的转折点，将影响临床实践、供应链设计和商业化策略。从仅限医院使用到门诊治疗以及潜在的植入式应用，需要一种综合性的方法，将技术创新与临床医生的工作流程、监管合规性和支付方的价值评估相结合。关税趋势和区域製造的考量进一步凸显了稳健的采购管道和贴近市场的生产模式的必要性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将穿戴式体外膜氧合系统整合到居家医疗环境中
  • 用于个人化人工肺治疗的3D列印肺泡支架的进展
  • 开发用于长期人工肺移植的生物相容性聚合物薄膜
  • 采用模组化人工肺装置支持患有慢性呼吸衰竭的儿童患者
  • 携带式氧合器系统的出现已在门诊病人临床试验中得到验证
  • 突破性疗法认定下的氧合肺装置快速核准监管途径
  • 透过生物技术公司和学术机构合作创建的生物工程肺组织构建体

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的氧合器市场

  • 体外膜氧合系统
    • 套管
    • 主机
    • 氧合设备
    • 泵浦
  • 植入式氧合器

第九章 人工肺市场：依技术划分

  • 陶瓷膜
  • 平面膜
  • 中空纤维膜
    • 聚醚砜
    • 聚丙烯

第十章 依最终用户分類的氧合器市场

  • 门诊治疗中心
  • 居家医疗
  • 医院

第十一章 人工肺市场：依应用领域划分

  • 加护治疗
  • 紧急运输
  • 呼吸辅助

第十二章 按分销通路分類的氧合器市场

  • 直销
    • 诊所帐户
    • 医院帐户
  • 经销商网络
    • 医疗设备批发商
    • 药品批发商
  • 线上平台

第十三章 依材料类型分類的氧合器市场

  • 聚醚砜
  • 聚丙烯
  • 硅酮

第十四章 人工肺市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 依组别分類的氧合器市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国氧合器市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Getinge AB
    • LivaNova PLC
    • Medtronic PLC
    • Terumo Corporation
    • Fresenius Medical Care AG & Co. KGaA
    • MC3 Cardiopulmonary Support Inc.
    • SynCardia Systems, LLC
    • ALung Technologies, Inc.
    • Aeson Cardiovascular AG
    • Hemovent GmbH
Product Code: MRR-1A1A064C0598

The Artificial Lung Market is projected to grow by USD 15.24 billion at a CAGR of 9.02% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.63 billion
Estimated Year [2025] USD 8.33 billion
Forecast Year [2032] USD 15.24 billion
CAGR (%) 9.02%

An integrative introduction to the evolving artificial lung landscape that connects advances in device engineering with shifting clinical practices and adoption imperatives

The artificial lung arena is rapidly maturing at the intersection of critical care innovation and advanced biomaterials engineering, driven by renewed clinical demand for alternatives to mechanical ventilation and improved outcomes in severe respiratory failure. Emerging device architectures aim to replicate pulmonary gas exchange with greater biocompatibility and portability, while procedural ecosystems adapt to integrate extracorporeal support earlier in the care pathway. As attention shifts from acute, in-hospital use toward ambulatory and home-support potential, developers and providers must reconcile intensive-care-grade performance with user-centric design and long-term safety profiles.

Concurrent advances in membrane technologies, pump miniaturization, and sensor-driven control systems are enabling more efficient extracorporeal platforms and nascent implantable solutions that could redefine chronic respiratory support. Regulatory frameworks and clinical evidence requirements are evolving to address these hybrid technologies, increasing the emphasis on real-world performance and human factors. Investors, supply chain partners, and clinical stakeholders are therefore tasked with navigating a highly technical landscape where translational research, manufacturability, and post-market surveillance are equally determinative of commercial success.

In this context, organizations should prioritize cross-disciplinary collaboration spanning materials science, critical care medicine, and regulatory strategy. By aligning technological roadmaps with clinical workflows and reimbursement realities, stakeholders can better bridge proof-of-concept milestones and sustainable adoption pathways for next-generation artificial lung systems.

How materials breakthroughs, miniaturization of support systems, and shifting care delivery models are jointly redefining pathways for artificial lung adoption and integration

Transformative shifts are reshaping the development and deployment of artificial lung technologies as clinical teams demand devices that deliver consistent gas exchange while minimizing thrombogenicity and inflammatory activation. Membrane material innovations are replacing legacy polymers with higher-performance ceramics and engineered hollow fibers, enhancing durability and hemocompatibility. At the same time, the miniaturization of drive consoles and the refinement of hemodynamic management algorithms are enabling more flexible deployment models, including mobile extracorporeal units and potential implantable constructs that are designed for longer-term support.

The clinical landscape is also changing in terms of care setting and stakeholder expectations. There is growing interest in extending extracorporeal support beyond intensive care units to pre-hospital emergency transport and ambulatory settings, which requires ruggedized devices, simplified interfaces, and telemonitoring capabilities. Concurrently, payer and procurement stakeholders are scrutinizing total cost of care and comparative effectiveness, pushing manufacturers to demonstrate not only technical superiority but also operational viability and clear pathways to reimbursement. These intersecting forces are producing a market environment where technological differentiation, clinical integration, and value demonstration are decisive for adoption trajectories.

Assessing the structural and operational consequences of escalated import duties in 2025 on supply chain resilience, sourcing strategies, and product development timelines

The imposition of new tariff regimes and trade measures in 2025 has introduced measurable friction across the supply chains that support artificial lung manufacturing and distribution. Increased duties on key imported components such as precision pumps, specialty membranes, and biocompatible polymers have elevated landed costs for assemblers that rely on cross-border sourcing. As a result, procurement teams and manufacturing planners are reassessing supplier concentration, hedging strategies, and contractual terms to preserve margin and continuity of supply.

Tariff-driven cost pressures have a cascading effect on product development timelines and commercial models. Engineering teams are under pressure to qualify alternative materials and suppliers more rapidly, while quality assurance functions must accelerate validation activities to maintain regulatory compliance. At the distribution level, channel partners are renegotiating pricing structures and service agreements to reflect higher input costs. Moreover, increased import duties are incentivizing nearshoring and regional manufacturing footprints, prompting capital allocation decisions to favor production sites closer to end markets to mitigate tariff exposure.

These dynamics also affect long-term strategic planning, as organizations balance the immediate need to absorb or pass through incremental costs with the broader objective of securing resilient supply chains. Stakeholders that proactively diversify supplier networks, invest in local manufacturing capability, and optimize product design for modularity are better positioned to manage tariff volatility while preserving access to critical components and technologies.

Actionable segmentation insights that connect product architecture, membrane technologies, end-user workflows, application scenarios, distribution approaches, and material selections to commercialization strategies

Understanding segmentation across product, technology, end user, application, distribution channel, and material type is essential for mapping value creation in the artificial lung domain. Product differentiation spans extracorporeal membrane oxygenation systems and investigational implantable artificial lungs, with extracorporeal systems further decomposed into cannula, consoles, oxygenators, and pumps that together determine procedural complexity and footprint. Technology choices range from ceramic and flat sheet membranes to hollow fiber configurations, and within hollow fibers, distinctions between polyethersulfone and polypropylene formulations inform trade-offs in permeability, durability, and hemocompatibility.

End users encompass ambulatory care centers, home care programs, and hospitals, each presenting distinct clinical workflows, staffing models, and procurement cycles that influence product requirements and support expectations. Applications vary across critical care, emergency transport, and respiratory support, and these use cases place different demands on device portability, setup time, and monitoring capabilities. Distribution channels include direct sales, distributor networks, and online platforms; direct sales models often target clinic and hospital accounts with integrated service offerings, while distributor relationships may leverage medical device and pharmaceutical distribution expertise to broaden market presence. Material selection, including polyethersulfone, polypropylene, and silicone, intersects with technology choice and device architecture to shape biocompatibility, sterilization pathways, and component longevity.

Taken together, these segmentation layers create a matrix of requirements that manufacturers must navigate. Product teams should align design specifications to the dominant combinations of technology, material, and end-user needs in their target geographies, while commercial teams should tailor channel strategies and service propositions to match the operational realities of hospitals, ambulatory centers, and home-based care providers.

Regional strategic imperatives that reconcile regulatory variation, clinical infrastructure, and manufacturing footprints to accelerate adoption of artificial lung technologies across global markets

Regional dynamics exert a powerful influence on regulatory expectations, reimbursement practices, and manufacturing logistics across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, clinical research networks and critical care infrastructure support advanced extracorporeal therapies, but market entry and scaling require navigation of diverse payer systems and hospital procurement protocols. Meanwhile, Europe, Middle East & Africa present a complex regulatory mosaic where harmonization efforts coexist with country-specific assessment criteria and procurement norms that shape deployment timelines and clinical evidence requirements.

Asia-Pacific markets demonstrate a spectrum of readiness, from high-volume, innovation-forward centers to regions prioritizing cost-effective and scalable solutions. Manufacturing capacity and supplier ecosystems in Asia-Pacific can offer competitive advantages for component sourcing, yet quality system alignment with international regulatory standards remains a critical gating factor. Across all regions, logistics, tariffs, and local clinical practice patterns inform decisions about regional production hubs, inventory positioning, and support infrastructure. Successful regional strategies integrate regulatory intelligence, localized clinical partnerships, and adaptive pricing models to align product value propositions with payer expectations and care delivery realities.

Organizations planning global rollouts should adopt a region-sensitive approach that sequences regulatory submissions, clinical engagements, and supply chain investments to reflect local priorities and operational constraints. This calibrated strategy reduces commercialization friction and accelerates meaningful clinical adoption across heterogeneous markets.

Key company patterns and competitive imperatives that prioritize membrane innovation, manufacturing rigor, clinical evidence generation, and channel orchestration for durable differentiation

Competitive dynamics in the artificial lung space are shaped by a mix of established medical device manufacturers, specialized component suppliers, and clinical innovators translating translational research into commercial prototypes. Key players invest in membrane science, pump efficiency, and integrated sensor systems to differentiate on performance, ease of use, and lifecycle costs. Strategic partnerships between device OEMs and materials specialists are increasingly common, enabling co-development of membrane structures and hemo-compatible coatings that reduce clot formation and inflammatory responses.

Beyond product innovation, companies that excel in commercialization are the ones that build robust clinical evidence generation programs and engage early with health technology assessment bodies. Manufacturing excellence and quality systems are equally critical; suppliers that can demonstrate scalable, reproducible production of membrane modules and precision pumps secure durable competitive advantages. Channel strategy also matters-organizations that combine direct clinical engagement with selective distributor relationships and digital platforms can extend reach while maintaining control over key customer interactions. Finally, leadership teams that prioritize post-market surveillance and iterative design improvements create a virtuous cycle of safety enhancements and clinician trust, which is especially important for devices that interface directly with blood and respiratory physiology.

High-impact recommendations for leaders to align modular engineering, supplier diversification, clinical evidence programs, and tailored commercial models to drive adoption and resilience

Industry leaders should pursue an integrated agenda that simultaneously addresses technological refinement, supply chain resilience, and clinical adoption pathways. Prioritizing modular device architectures will accelerate qualification of alternative suppliers and support iterative product updates without wholesale platform redesign. Investments in membrane and coating technologies should be coupled with rigorous hemocompatibility testing and human factors engineering to reduce adverse events and simplify clinician workflows. On the supply chain front, diversifying component sources and exploring regional manufacturing nodes can mitigate tariff exposure and logistical disruption while shortening lead times for critical assemblies.

Commercially, organizations should align go-to-market models to end-user needs by tailoring service bundles for hospitals, ambulatory centers, and home care settings, and by building training and remote-monitoring capabilities that lower barriers to adoption. Regulatory strategy must be proactive, embedding post-market data strategies and health economic modeling into submissions to demonstrate clinical utility and value to payers. Finally, leadership should institutionalize scenario-based planning to stress-test product roadmaps against policy shifts, supply interruptions, and payer behavior changes. These parallel actions will strengthen an organization's ability to convert engineering innovation into reliable, widely adopted clinical solutions.

A transparent, evidence-driven methodology integrating clinician interviews, materials and device analyses, supply chain mapping, and scenario testing to inform strategic decision-making

The research approach combines a multi-source evidence base, qualitative expert interviews, and structured analysis to create a comprehensive view of the artificial lung landscape. Primary inputs include discussions with clinicians, biomedical engineers, regulatory advisers, and procurement specialists to capture clinical workflows, device performance priorities, and real-world adoption barriers. Secondary research encompasses peer-reviewed literature, regulatory guidance documents, patents, and manufacturer technical specifications to triangulate technological trends and materials science advances. Comparative analysis of device architectures and supply chain footprints supports assessments of manufacturability and logistical risk.

Analytical methods include technology mapping to compare membrane types and pump platforms, value-chain decomposition to highlight cost and quality drivers, and scenario analysis to anticipate operational responses to policy shifts and tariff changes. Quality control measures include cross-validation of claims with multiple independent sources and critical appraisal of evidence quality for clinical outcomes. The methodology emphasizes transparency in assumptions and traceability of data sources while refraining from projecting numerical market estimates. This layered approach ensures the findings are grounded in empirical evidence and stakeholder perspectives, supporting actionable insights for developers, payers, and providers.

A conclusive synthesis that ties material science breakthroughs, device portability, regulatory alignment, and supply chain resilience into pragmatic pathways for clinical adoption and commercialization

In conclusion, advances in membrane materials, device miniaturization, and systems integration are converging to create an inflection point in artificial lung technologies, with implications for clinical practice, supply chain design, and commercialization strategies. The movement from exclusively in-hospital use toward ambulatory and potentially implantable applications requires a holistic approach that aligns engineering innovation with clinician workflows, regulatory compliance, and payer value assessment. Tariff dynamics and regional manufacturing considerations further underscore the need for resilient sourcing and near-market production options.

Stakeholders that adopt a segmented, regionally aware strategy-one that synchronizes product design, channel approach, and evidence generation-will be better positioned to navigate the complex path from prototype to clinical standard of care. Ultimately, the organizations most likely to succeed will be those that combine technical excellence in membrane and pump systems with disciplined commercialization practices, robust quality systems, and an adaptive supply chain capable of responding to policy and market shocks. This integrated posture will accelerate the translation of technological promise into tangible clinical benefits for patients with severe respiratory insufficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of wearable extracorporeal membrane oxygenation systems into home care settings
  • 5.2. Advancements in 3d printed alveolar scaffolds for personalized artificial lung therapies
  • 5.3. Development of biocompatible polymer membranes for long term artificial lung implants
  • 5.4. Adoption of modular artificial lung devices to support pediatric patients with chronic respiratory failure
  • 5.5. Emergence of portable artificial lung systems validated in ambulatory patient clinical trials
  • 5.6. Regulatory pathways for accelerated approval of artificial lung devices under breakthrough designations
  • 5.7. Collaborations between biotech firms and academic centers to create bioengineered lung tissue constructs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Lung Market, by Product Type

  • 8.1. Extracorporeal Membrane Oxygenation System
    • 8.1.1. Cannula
    • 8.1.2. Console
    • 8.1.3. Oxygenator
    • 8.1.4. Pump
  • 8.2. Implantable Artificial Lung

9. Artificial Lung Market, by Technology

  • 9.1. Ceramic Membrane
  • 9.2. Flat Sheet Membrane
  • 9.3. Hollow Fiber Membrane
    • 9.3.1. Polyethersulfone
    • 9.3.2. Polypropylene

10. Artificial Lung Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Home Care
  • 10.3. Hospitals

11. Artificial Lung Market, by Application

  • 11.1. Critical Care
  • 11.2. Emergency Transport
  • 11.3. Respiratory Support

12. Artificial Lung Market, by Distribution Channel

  • 12.1. Direct Sales
    • 12.1.1. Clinic Accounts
    • 12.1.2. Hospital Accounts
  • 12.2. Distributor Network
    • 12.2.1. Medical Device Distributors
    • 12.2.2. Pharmaceutical Distributors
  • 12.3. Online Platforms

13. Artificial Lung Market, by Material Type

  • 13.1. Polyethersulfone
  • 13.2. Polypropylene
  • 13.3. Silicone

14. Artificial Lung Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Artificial Lung Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Artificial Lung Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Getinge AB
    • 17.3.2. LivaNova PLC
    • 17.3.3. Medtronic PLC
    • 17.3.4. Terumo Corporation
    • 17.3.5. Fresenius Medical Care AG & Co. KGaA
    • 17.3.6. MC3 Cardiopulmonary Support Inc.
    • 17.3.7. SynCardia Systems, LLC
    • 17.3.8. ALung Technologies, Inc.
    • 17.3.9. Aeson Cardiovascular AG
    • 17.3.10. Hemovent GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL LUNG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ARTIFICIAL LUNG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ARTIFICIAL LUNG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ARTIFICIAL LUNG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ARTIFICIAL LUNG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL LUNG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CANNULA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CONSOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY OXYGENATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY IMPLANTABLE ARTIFICIAL LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CERAMIC MEMBRANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY FLAT SHEET MEMBRANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CRITICAL CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY EMERGENCY TRANSPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY RESPIRATORY SUPPORT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY CLINIC ACCOUNTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY HOSPITAL ACCOUNTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MEDICAL DEVICE DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY PHARMACEUTICAL DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYETHERSULFONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY POLYPROPYLENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY SILICONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ARTIFICIAL LUNG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY HOLLOW FIBER MEMBRANE, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY DISTRIBUTOR NETWORK, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST ARTIFICIAL LUNG MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 326. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 327. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. AFRICA ARTIFICIAL LUNG MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)

TA